Tower Research Capital LLC TRC Raises Position in Simulations Plus, Inc. (NASDAQ:SLP)

Tower Research Capital LLC TRC raised its position in Simulations Plus, Inc. (NASDAQ:SLP) by 42.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,575 shares of the technology company’s stock after buying an additional 764 shares during the period. Tower Research Capital LLC TRC’s holdings in Simulations Plus were worth $72,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in shares of Simulations Plus by 6.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 419,241 shares of the technology company’s stock worth $11,693,000 after acquiring an additional 24,266 shares during the last quarter. First Trust Advisors LP lifted its holdings in Simulations Plus by 47.3% in the 4th quarter. First Trust Advisors LP now owns 9,393 shares of the technology company’s stock valued at $262,000 after purchasing an additional 3,015 shares in the last quarter. Marshall Wace LLP boosted its stake in Simulations Plus by 116.2% during the 4th quarter. Marshall Wace LLP now owns 102,077 shares of the technology company’s stock worth $2,847,000 after purchasing an additional 54,858 shares during the last quarter. Barclays PLC grew its holdings in shares of Simulations Plus by 2.7% during the fourth quarter. Barclays PLC now owns 29,229 shares of the technology company’s stock worth $815,000 after buying an additional 756 shares in the last quarter. Finally, Kennedy Capital Management LLC raised its position in shares of Simulations Plus by 59.4% in the fourth quarter. Kennedy Capital Management LLC now owns 289,286 shares of the technology company’s stock valued at $8,068,000 after buying an additional 107,766 shares during the last quarter. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $33.51, for a total transaction of $670,200.00. Following the completion of the transaction, the director now owns 3,344,157 shares of the company’s stock, valued at approximately $112,062,701.07. This trade represents a 0.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 19.40% of the company’s stock.

Analysts Set New Price Targets

SLP has been the subject of several research reports. StockNews.com raised shares of Simulations Plus from a “sell” rating to a “hold” rating in a research note on Monday, April 28th. KeyCorp upped their price target on Simulations Plus from $32.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, April 16th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Simulations Plus currently has an average rating of “Moderate Buy” and an average price target of $50.00.

Simulations Plus Price Performance

NASDAQ:SLP opened at $30.02 on Friday. The company’s 50-day moving average is $28.76 and its two-hundred day moving average is $30.23. The firm has a market capitalization of $603.73 million, a price-to-earnings ratio of 75.05 and a beta of 1.10. Simulations Plus, Inc. has a 1-year low of $23.01 and a 1-year high of $51.22.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Thursday, April 3rd. The technology company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.06. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The company had revenue of $22.43 million during the quarter, compared to analyst estimates of $21.93 million. During the same period in the prior year, the business posted $0.20 earnings per share. The firm’s revenue for the quarter was up 22.5% compared to the same quarter last year. As a group, equities analysts anticipate that Simulations Plus, Inc. will post 1.09 earnings per share for the current fiscal year.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.